- AUD/USD benefits from the recent recovery in risks.
- Gilead’s remdesivir is getting noticeable success in clinical trials.
- US dollar strength, risk-off dominated market mood earlier.
- China's data, mainly the GDP, will be the key to watch while virus updates could keep markets entertained.
AUD/USD cheers the success of Gilead’s remdesivir clinical trials while rising to 0.6365, up 0.60% on a day, during the early Friday morning in Asia. In doing so, the Aussie pair bucks the previous day’s downbeat performance, portrayed mainly due to the broad US dollar strength and risk-off, while waiting for China’s key data.
Following the CNBC news suggesting the Gilead Life Science’s remdesivir is getting a huge success ratio during the clinical trials, markets dumped the previous risk-off with the S&P 500 ETF surging 2.0%.
Earlier, Wall Street managed to avoid losses with US President Donald Trump pushing for the phased re-open of the economy but the Treasury yields remain on the back foot amid worries concerning the coronavirus (COVID-19) crisis.
The pandemic issue remains center to market performance as there have been more than two million confirmed cases and the US death toll nears 31,000. This pushes New York to extend the lockdown, with Japan also announcing national emergency, but Switzerland bucks the trend to cite the restrictions’ exit measures. On Thursday, Aussie PM Scott Morrison also signaled for an exit strategy but also said, “need to be prepared for very sobering economic news in the months ahead.”
While the recent updates concerning the cure are likely to help the Aussie pair, major attention will be on China’s first quarter (Q1) GDP and March month Industrial Production, coupled with Retail Sales, figures. Although forecasts suggest downbeat figures for each of the key economic indicators, outcomes from the dragon nation have recently surprised markets. Hence, any such repetition of the surprises could offer an additional boost to the present risk reset, also propelling the Aussie quote.
Technical analysis
Failure to provide a sustained break below the monthly support-line, currently at 0.6315, pushes the pair towards confronting a 50-day SMA level of 0.6365. Though, 0.6400 and Wednesday’s high near 0.6445 hold the gate for further upside. Alternatively, downside below 0.6315 could revisit the March-end top near 0.6215/10.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD trades weak below 1.0800 amid Good Friday lull, ahead of US PCE
EUR/USD remains depressed below 1.0800 after soft French inflation data, amid minimal volatility and thin liquidity on Good Friday. The pair keenly awaits the US PCE inflation data and Fed Chair Powell's speech for fresh hints on next week's price action.
GBP/USD holds steady above 1.2600 as markets stay calm on Good Friday
GBP/USD trades sideways above 1.2600 amid a typical Good Friday trading lull. A broadly firmer US Dollar could keep any upside attempts limited in the pair ahead of the US PCE inflation data and Fed Chair Powell's appearance.
Gold price sits at all-time highs above $2,230, US PCE eyed
Gold price hit all-time highs at $2,236 on Thursday to finish Q1 2024 with a bang. Most major world markets, including the US are closed due to Holy Friday, leaving volatility around Gold price highly subdued. US PCE inflation and Powell are awaited.
Jito price could hit $6 as JTO coils up inside this bullish pattern
Jito (JTO) price has been on an uptrend since forming a local bottom in early January. Since then, JTO has revisited the key swing point formed in early December, suggesting the bulls’ intention to move higher.
Key events in developed markets next week
Next week, the main focus will be inflation and the labour market in the Eurozone. We expect services inflation to be impacted by the easter effect, while the unemployment rate to be unchanged.